

Point-of-care testing for gastrointestinal pathogens

Submission date 20/02/2017	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 21/02/2017	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 10/05/2023	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Many adults patient are admitted to hospital with diarrhoea every year. Some of these patients have infections and some have diarrhoea for other reasons. Patients with infections need to be isolated in a side room quickly to stop their infection from spreading to other patients. Some patients with infection will also need specific antibiotic treatment whilst others will not. The current tests that the NHS uses to look for infection in patients with diarrhoea take up to 5 days for a result. This means whilst the test result is awaited all patients with diarrhoea are put in a side room in case they have an infection and doctors have to make an educated guess as to who to treat with antibiotics. There are new tests available that are as accurate as standard laboratory tests and can generate a result in one hour. These are called molecular, point-of-care tests (POCT). The testing device is small and easy to use and so can be used at the patient's bedside rather than in a laboratory. This means that when a patient comes in with diarrhoea the doctors can know very quickly if they need to be isolated and if they need antibiotics or not. As the test is new there is no information as to whether testing patients like this will improve their care or be cost effective for the NHS. The aim of this study is to find out whether using this new test at patient's bedsides improves the way they are cared for and the way that side rooms are used in hospital.

Who can participate?

Adult patients in a Southampton General Hospital who have had sudden diarrhoea or vomiting.

What does the study involve?

Participants are randomly allocated to one of two groups. Those in the first group have their stools tested immediately using the molecular, point-of-care test (POCT) device. The results are then passed onto the healthcare team so that they can start antibiotic treatment if they need it. A further stool sample is also taken to be stored and tested at a later date. Those in the second group are managed according to standard practices, which involve having stool samples sent to the laboratory for testing. Throughout their hospital stay, patients in both groups have their medical records reviewed in order to find out how long they are kept in isolation in a side room and what care they receive, as well as completing an optional survey about their satisfaction with the care received.

What are the possible benefits and risks of participating?

It is not known whether having the new test will lead to improvements in patient care but it is possible that patients will directly benefit in terms of being cared for in the correct environment and having the antibiotic treatment given or withheld as appropriate. There are no anticipated risks involved with participating.

Where is the study run from?

Southampton General Hospital (UK)

When is the study starting and how long is it expected to run for?

September 2016 to March 2020

Who is funding the study?

Biofire Diagnostics, LLC (UK)

Who is the main contact?

Ms Emma Levell

emma.levell@uhs.nhs.uk

Contact information

Type(s)

Scientific

Contact name

Dr Tristan Clark

Contact details

University of Southampton Faculty of Medicine and University Hospital Southampton NHS

Foundation LF101, Level F, South Academic Block

Southampton General Hospital

Tremona Road

Southampton

United Kingdom

SO16 6YD

+44 (0)2381 290 8410

t.w.clark@soton.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

33068

Study information

Scientific Title

Randomised controlled trial comparing syndromic molecular point-of-care testing for gastrointestinal pathogens with standard clinical care, in adults presenting to secondary care with suspected infectious gastroenteritis (GastroPOC Trial)

Acronym

GastroPOC

Study objectives

The aim of this study is to examine the clinical impact of a rapid, molecular, point-of-care test (POCT) for gastrointestinal pathogens detection (FilmArray Gastrointestinal Panel, BioFire, Salt Lake City, Utah, USA, owned by bioMérieux; CE marked) in patients presenting with acute diarrhoea and/or vomiting, compared to routine clinical care.

Ethics approval required

Old ethics approval format

Ethics approval(s)

West Midlands - Solihull Research Ethics Committee, 09/01/2017, ref: 16/WM/0515

Study design

Randomised; Interventional; Design type: Diagnosis, Process of Care, Device

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

See additional files

Health condition(s) or problem(s) studied

Gastroenteritis

Interventions

Participants will be randomised to one of two groups in a 1:1 ratio using an internet-based randomisation service using random permuted blocks of varying sizes (4, 6 and 8).

Intervention group: Participants will have a molecular Point-of-Care test (POCT) performed on stool with the results immediately communicated to the clinical team, infection prevention and control (IPAC) team and the patient. Subsequent clinical management decisions are made independently by the responsible clinical and IPAC teams.

Control group: Participants will be managed according to routine clinical care, where testing for pathogens in stool is at the discretion of the responsible clinical team and where performed will use the standard NHS laboratory testing. A stool sample also will be taken and stored and tested at later date with the POCT to allow direct comparison of the pathogens detected between the groups (i.e. missed diagnoses).

For participants in both groups, clinical and demographic data is collected at enrolment and for outcome measures is collected retrospectively from case notes and electronic hospital information systems. Patient satisfaction surveys are performed immediately prior to discharge. There is no follow up.

Intervention Type

Other

Primary outcome measure

Duration of time in side room isolation is measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)

Secondary outcome measures

1. Proportion of patients isolated in a side room is measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)
2. Time to patient isolation in a side room is measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)
3. Time to de-isolation in pathogen negative patients is measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)
4. Proportion of patients treated with antibiotics is measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)
5. Time to treatment with antibiotics is measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)
6. Duration of antibiotics is measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)
7. Duration of hospitalisation is measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)
8. Proportion of patients with a pathogen detected is measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)
9. Time to diagnosis is measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)
10. Concordance between results obtained from rectal swab and stool culture is measured retrospectively at a time point >30 days post enrolment by comparing the result of diagnostic

testing

11. Turnaround time is measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)

12. Patient satisfaction is measured using a validating NHS survey tool at the point of discharge

13. Safety is measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)

Added 21/03/2019:

14. Proportion of pathogen-positive patients de-isolated, measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)

15. Proportion of pathogen-negative patients de-isolated, measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)

Added 04/09/2020:

Measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days where appropriate):

16. Duration of time in a side room for pathogen positive patients

17. Duration of time in a side room for pathogen negative patients

18. Proportion of pathogen positive patients isolated in a side room

19. Proportion of pathogen negative patients isolated in a side room

20. Proportion of patients with bacterial gastroenteritis treated with antibiotics

21. Proportion of patients without bacterial gastroenteritis treated with antibiotics

22. Other medication use, complications (inc Acute Kidney Injury), ICU admissions, 30-day mortality, representation and readmission

Added 28/05/2021:

Missed diagnoses measured by retrospective review of case notes and electronic hospital information systems for the duration of hospitalisation (up to 30 days maximum)

Overall study start date

01/09/2016

Completion date

17/03/2020

Eligibility

Key inclusion criteria

1. Aged 18 years or over

2. Has the capacity to give informed, written consent and is able and willing to adhere to the study procedures

3. A patient in Southampton General Hospital ED, AMU, ASU or inpatient ward (if admitted directly to an inpatient ward)

4. Can be recruited to the study within a 48 hour period of first triage by ED staff OR within a 48 hour period of arrival on AMU or ASU or inpatient ward (if admitted directly to AMU/ASU to these areas)

5. Has an acute diarrhoeal illness and/or vomiting*

5. Has a duration of illness less of than or equal to 14 days

*An episode of acute diarrhoea is defined as the passage of at least 3 loose stools for at least 1 day.

(AMU = acute medical unit, ASU = acute surgical unit, ED = emergency department)

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned Sample Size: 300; UK Sample Size: 300

Total final enrolment

278

Key exclusion criteria

1. Patients not fulfilling inclusion criteria
2. A palliative approach being taken by the treating clinicians
3. Previously included in this study and re-presenting within the last 30 days after hospital discharge
4. Declines to give stool sample and/or rectal swab

Involvement in other research trials is not necessarily an exclusion criterion. Concurrent, prior or subsequent enrolment in an observational study is not expected to be an exclusion criterion, except at the discretion of the principal investigator.

Date of first enrolment

01/03/2017

Date of final enrolment

01/03/2020

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre

Southampton General Hospital

Tremona Road

Southampton
United Kingdom
SO16 6YD

Sponsor information

Organisation

University Hospital Southampton NHS Foundation Trust

Sponsor details

Mailpoint 18
Southampton General Hospital
Tremona Road
Southampton
England
United Kingdom
SO16 6YD

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/0485axj58>

Funder(s)

Funder type

Industry

Funder Name

Biofire Diagnostics, LLC

Results and Publications

Publication and dissemination plan

The findings of this study will be disseminated locally and regionally and will be presented at national and international scientific meetings. The results will be published in high impact peer-reviewed scientific journals.

Intention to publish date

31/12/2022

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Prof. Tristan Clark or Dr Nathan Brendish (t.w.clark@soton.ac.uk, n.brendish@soton.ac.uk); data are available upon reasonable request, participants' data are fully anonymised, and all participants have given written consent for future data use.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	version V2.1	26/01/2017	21/02/2017	No	Yes
Protocol (other)	version 2.0	16/06/2021	10/10/2022	No	No
Protocol file		30/05/2018	10/10/2022	No	No
Results article		25/04/2023	02/05/2023	Yes	No
HRA research summary			28/06/2023	No	No